Q-omics provides the consensus-scored LRTOMT profile across patient tissues and cancer cell-line models. LRTOMT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LRTOMT is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LRTOMT RNA expression shows 20,936 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where LRTOMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRTOMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRTOMT survival associations across molecular data types. LRTOMT RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRTOMT RNA expression–survival associations across cancer types. High LRTOMT expression shows unfavorable associations in KICH and ACC, but favorable associations in SKCM, BRCA, UCEC and THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for LRTOMT RNA expression.
This table summarizes LRTOMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRTOMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRTOMT shows lower tumor expression in THCA, KIRC, KICH and LUAD and higher tumor expression in LIHC and BRCA. The THCA box plot shows higher LRTOMT RNA expression in normal versus tumor tissue (log2 FC = −1.156, t-test p < 0.001).
This table shows molecular features associated with LRTOMT in patient tissues and cancer cell lines. In patient samples, LRTOMT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRTOMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
